Experimental drug could lead to substantial weight reduction | The IndependentNotifications can be managed in browser preferences.Jump to contentIndependentIndependent Bulletin homepageSocial PartnerWe are 8 logo (opens in a new tab)AllNewsSportCultureLifestyleVishwam SankaranTuesday 24 June 2025 09:31 BSTExperts warn that weight-loss jabs may need to be taken for lifeA new experimental drug, Maridebart cafraglutide (MariTide), shows promise for significant weight reduction and treating obesity and type 2 diabetes.Clinical trial results indicate MariTide can reduce body weight by up to 20 per cent within a year, with weight loss continuing beyond 12 months.The drug targets similar molecules as popular weight loss jabs like Ozempic and also affects insulin release, leading to improved heart health measures.MariTide's once-a-month or less frequent dosing schedule could enhance patient adherence and provide sustainable, long-term weight control.While some mild to moderate gut-related side effects were noted, they were manageable, and researchers are now exploring the drug's further efficacy and use in other conditions.In fullNew once-a-month drug could treat diabetes and obesity, scientists sayThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in